These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17077156)

  • 1. Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted.
    Madhok R; Wu O; McKellar G; Singh G
    Rheumatology (Oxford); 2006 Dec; 45(12):1458-60. PubMed ID: 17077156
    [No Abstract]   [Full Text] [Related]  

  • 2. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Woodruff T
    Intern Med J; 2006 Dec; 36(12):797-8; author reply 798-9. PubMed ID: 17096747
    [No Abstract]   [Full Text] [Related]  

  • 3. Parecoxib - getting to the heart of the matter.
    Schug SA; Joshi GP; Camu F
    Anaesthesia; 2007 Mar; 62(3):291-2; author reply 292. PubMed ID: 17300311
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Farkouh ME; Greenberg BP
    Am J Cardiol; 2009 May; 103(9):1227-37. PubMed ID: 19406264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NSAIDs and cardiovascular disease.
    Patrignani P; Capone ML; Tacconelli S
    Heart; 2008 Apr; 94(4):395-7. PubMed ID: 18347364
    [No Abstract]   [Full Text] [Related]  

  • 8. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM
    Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Guo ZR
    Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular effects of low-dose aspirin, traditional non-steroidal anti-inflammatory drugs and coxibs.
    Patrono C
    Bull Mem Acad R Med Belg; 2010; 165(1-2):115-23; discussion 124. PubMed ID: 21162342
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of dosage on coxib- or nonsteroidal antiinflammatory drug-associated cardiovascular risk? Comment on the article by Solomon et al.
    Boers M
    Arthritis Rheum; 2007 Jan; 56(1):384; author reply 384. PubMed ID: 17195242
    [No Abstract]   [Full Text] [Related]  

  • 12. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.
    ; Wilcox CM; Allison J; Benzuly K; Borum M; Cryer B; Grosser T; Hunt R; Ladabaum U; Lanas A; Paulus H; Regueiro C; Sandler RS; Simon L
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1082-9. PubMed ID: 16877048
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk.
    U.S. Food and Drug Administration
    J Pain Palliat Care Pharmacother; 2005; 19(4):83-97. PubMed ID: 16431839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Nurmohamed MT
    Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1313; author reply 1313-4. PubMed ID: 17624165
    [No Abstract]   [Full Text] [Related]  

  • 15. [Coxibes--bullying of a drug class?].
    Müller P; Simon B
    MMW Fortschr Med; 2008 Jun; 150 Suppl 2():63-4. PubMed ID: 18712125
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
    Hennekens CH; Borzak S
    J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):41-50. PubMed ID: 18287589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular adverse reactions from NSAIDs are more than COX-2 inhibition alone.
    Rainsford KD
    Rheumatology (Oxford); 2010 May; 49(5):834-6. PubMed ID: 20097907
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular toxicity of nonsteroidal anti-inflammatory drugs: moving beyond cyclooxygenase selectivity.
    Mangoni AA; Crilly MA; Knights KM
    Expert Rev Clin Pharmacol; 2011 May; 4(3):299-302. PubMed ID: 22114775
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular and gastrointestinal risks of nonsteroidal antiinflammatory drugs revisited: comment on the article by the American College of rheumatology Ad Hoc group on use of selective and nonselective nonsteroidal antiinflammatory drugs.
    Rothschild B
    Arthritis Rheum; 2009 Feb; 61(2):284-5, author reply 285-6. PubMed ID: 19177539
    [No Abstract]   [Full Text] [Related]  

  • 20. Do case control studies on coxibs tell us anything new?
    Brune K
    Rheumatology (Oxford); 2007 May; 46(5):730. PubMed ID: 17309891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.